We are located in Paris
At MedInsights, we aim to revolutionize metabolic disease treatment. Our core strength lies in Nexus-Rx, an advanced drug identification and optimization engine. By integrating proprietary explainable AI models with deep graph learning technologies, we identify unknown and unforeseen relationships between disease-targets-drugs. These predicted candidates are rigorously validated through preclinical and clinical collaborations, to ultimately deliver transformative therapies to patients.
​
​
We are a AI driven biotech company with a vision to transform the treatment landscape for metabo-inflammatory diseases. Our commitment to innovation and patient-centricity fuels our drive to deliver effective, targeted therapies.
​
Introducing Our Fully-Integrated Drug Discovery Framework NEXUS-Rx
-
Unified data umbrella: Seamlessly generate insights from over 25+ sources, including clinical trials, publications, omics datasets, patents, anonymized patient datasets (proprietary) and other specialized databases (internal and external).
-
Navigating the Disease Landscape: Generate comprehensive network models that visualize disease progression and drug interactions at the molecular level.
-
Exploring Hidden Connections: Find correspondence between networks to to identify promising drug-disease matches that might have been missed.
-
Expansion of Treatment Options: Uncover novel uses for existing medications based on their interaction with disease pathways and pharmacological actions.
-
Accelerate Drug Development: Pinpoint promising drug leads with high potential for further development.
-
Optimize Clinical Trials: Clinical endpoint mapping and adverse events mapping facilitates identification of potential biomarkers that can streamline drug development by analyzing previous treatment response in patients.
How NEXUS-Rx works?
OUR CLIENT PORTFOLIO
"My research team is primarily focused on the physiology of body weight homeostasis and food intake. A strong component of our work encompass physiological approaches of brain circuits dictating metabolic control. With the emergence of omics technology it has become crucial to benefit from an expertise in bio informatics. My encounter with MedInsights was a revelation in that regards because the company not only has cutting edge knowledge and tools but also-which is quite unique in my experience-is offering mentoring and training support for post-doc and fellows to develop an understanding of the pipeline of analysis and procedure to be followed. MedInsights has been giving talks in my lab on several occasion and we are now actively seeking to make MedInsights part of of all our developing projects in which their expertise and knowledge has become a crucial determinant of competitivity in academic publication, data analysis and fund raising."
Prof. Serge Luquet
Université Paris Cité BFA UMR CNRS 8251
MEMBERSHIPS
MedInsights is a part of REPO4EU and Paris Biotech Santé
